Kinetic, thermodynamic, and structural characterizationsxs of the association between Nrf2-DLGex degron and Keap1

Molecular and Cellular Biology

Volumn 34, Issue 5, 2014, Pages 832-846

  Fukutomi, Toshiaki ^a   Takagi, Kenji ^b   Mizushima, Tsunehiro ^b   Ohuchi, Noriaki ^a   Yamamoto, Masayuki ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF HYOGO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NF-E2-RELATED FACTOR 2; PROTEIN BINDING; THERMODYNAMICS;

EID: 84893840509     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01191-13     Document Type: Article

References (49)

1. Motohashi H, O'Connor T, Katsuoka F, Engel JD, Yamamoto M. 2002. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene 294:1-12. http://dx.doi.org/10.1016/S0378-1119(02)00788-6.
2. Kobayashi M, Yamamoto M. 2006. Nrf2-Keap1 regulation of cellular defense mechanisms against electrophiles and reactive oxygen species. Adv. Enzyme Regul. 46:113-140. http://dx.doi.org/10.1016/j.advenzreg.2006.01.007.
3. Taguchi K, Motohashi H, Yamamoto M. 2011. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16:123-140. http://dx.doi.org/10.1111/j.1365-2443.2010.01473.x.
4. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, Yamamoto M. 1999. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:76-86.
5. Tong KI, Kobayashi A, Katsuoka F, Yamamoto M. 2006. Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol. Chem. 387:1311-1320.
6. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M. 2004. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 24:7130-7139. http://dx.doi.org/10.1128/MCB.24.16.7130-7139.2004.
7. Katoh Y, Iida K, Kang MI, Kobayashi A, Mizukami M, Tong KI, McMahon M, Hayes JD, Itoh K, Yamamoto M. 2005. Evolutionary conserved N-terminal domain of Nrf2 is essential for the Keap1-mediated degradation of the protein by proteasome. Arch. Biochem. Biophys. 433: 342-350. http://dx.doi.org/10.1016/j.abb.2004.10.012.
8. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. 2004. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redoxinsensitive Neh6 degron. J. Biol. Chem. 279:31556-31567. http://dx.doi.org/10.1074/jbc.M403061200.
9. Tong KI, Padmanabhan B, Kobayashi A, Shang C, Hirotsu Y, Yokoyama S, Yamamoto M. 2007. Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response. Mol. Cell. Biol. 27:7511-7521. http://dx.doi.org/10.1128/MCB.00753-07.
10. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, Yamamoto M. 2006. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell. Biol. 26:2887-2900. http://dx.doi.org/10.1128/MCB.26.8.2887-2900.2006.
11. Ogura T, Tong KI, Mio K, Maruyama Y, Kurokawa H, Sato C, Yamamoto M. 2010. Keap1 is a forked-stem dimer structure with two large spheres enclosing the intervening, double glycine repeat, and C-terminal domains. Proc. Natl. Acad. Sci. U. S. A. 107:2842-2847. http://dx.doi.org/10.1073/pnas.0914036107.
12. Suzuki T, Shibata T, Takaya K, Shiraishi K, Kohno T, Kunitoh H, Tsuta K, Furuta K, Goto K, Hosoda F, Sakamoto H, Motohashi H, Yamamoto M. 2013. Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels. Mol. Cell. Biol. 33:2402-2412. http://dx.doi.org/10.1128/MCB.00065-13.
13. Uruno A, Furusawa Y, Yagishita Y, Fukutomi T, Muramatsu H, Negishi T, Sugawara A, Kensler TW, Yamamoto M. 2013. The Keap1-Nrf2 system prevents onset of diabetes mellitus. Mol. Cell. Biol. 33:2996-3010. http://dx.doi.org/10.1128/MCB.00225-13.
14. Joshi G, Johnson JA. 2012. The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases. Recent Pat. CNS Drug Discov. 7:218-229. http://dx.doi.org/10.2174/157488912803252023.
15. Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M, Kensler TW. 2003. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 24:461-467. http://dx.doi.org/10.1093/carcin/24.3.461.
16. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H, Yamamoto M. 2004. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 64:6424-6431. http://dx.doi.org/10.1158/0008-5472.CAN-04-1906.
17. Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M. 2013. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res. 73:4158-4168. http://dx.doi.org/10.1158/0008-5472.CAN-12-4499.
18. Ohkoshi A, Suzuki T, Ono M, Kobayashi T, Yamamoto M. 2013. Role of Keap1-Nrf2 system in upper aerodigestive tract carcinogenesis. Cancer Prev. Res. 6:149 -159. http://dx.doi.org/10.1158/1940-6207.CAPR-12-0401-T.
19. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M, Hirohashi S. 2008. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. U. S. A. 105:13568-13573. http://dx.doi.org/10.1073/pnas.0806268105.
20. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. 2010. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid. Redox Signal. 13:1627-1637. http://dx.doi.org/10.1089/ars.2010.3219.
21. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, Wu H, Bova SG, Biswal S. 2010. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol. Cancer Ther. 9:336- 346. http://dx.doi.org/10.1158/1535-7163.MCT-09-0589.
22. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, Yoshimatsu Y, Tachimori Y, Kushima R, Kiyono T, Yamamoto M. 2011. NRF2 Mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 13:864-873. http://dx.doi.org/10.1593/neo.11750.
23. Sasaki H, Hikosaka Y, Okuda K, Kawano O, Moriyama S, Yano M, Fujii Y. 2010. NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J. Thorac. Oncol. 5:786-789. http://dx.doi.org/10.1097/JTO.0b013e3181db3dd3.
24. Takahashi T, Sonobe M, Menju T, Nakayama E, Mino N, Iwakiri S, Nagai S, Sato K, Miyahara R, Okubo K, Hirata T, Date H, Wada H. 2010. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J. Surg. Oncol. 101:500-506. http://dx.doi.org/10.1002/jso.21520.
25. Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A, Sasano H, Nakagawa T, Satoh K, Tanaka N, Kubo H, Motohashi H, Yamamoto M. 2012. Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci. 103:760-766. http://dx.doi.org/10.1111/j.1349-7006.2012.02216.x.
26. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T, Hoshii T, Hirao A, Takagi K, Mizushima T, Motohashi H, Lee MS, Yoshimori T, Tanaka K, Yamamoto M, Komatsu M. 2013. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol. Cell 51:618-631. http://dx.doi.org/10.1016/j.molcel.2013.08.003.
27. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326. http://dx.doi.org/10.1016/S0076-6879(97)76066-X.
28. Vagin A, Teplyakov A. 2010. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66:22-25. http://dx.doi.org/10.1107/S0907444909042589.
29. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132. http://dx.doi.org/10.1107/S0907444904019158.
30. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr.DBiol. Crystallogr. 53:240-255. http://dx.doi.org/10.1107/S0907444996012255.
31. Adams PD, Afonine PV, Bunkóczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66: 213-221. http://dx.doi.org/10.1107/S0907444909052925.
32. Hu Y, Ju Y, Lin D, Wang Z, Huang Y, Zhang S, Wu C, Jiao S. 2012. Mutation of the Nrf2 gene in non-small cell lung cancer. Mol. Biol. Rep. 39:4743-4747. http://dx.doi.org/10.1007/s11033-011-1266-4.
33. Cho HY. 2013. Genomic structure and variation of nuclear factor (erythroid- derived 2)-like 2. Oxid. Med. Cell. Longev. 2013:286524. http://dx.doi.org/10.1155/2013/286524.
34. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39:D945- D950. http://dx.doi.org/10.1093/nar/gkq929.
35. Niesen FH, Berglund H, Vedadi M. 2007. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2:2212-2221. http://dx.doi.org/10.1038/nprot.2007.321.
36. Leavitt S, Freire E. 2001. Direct measurement of protein binding energetics by isothermal titration calorimetry. Curr. Opin. Struct. Biol. 11: 560-566. http://dx.doi.org/10.1016/S0959-440X(00)00248-7.
37. Huang HC, Nguyen T, Pickett CB. 2002. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response elementmediated transcription. J. Biol. Chem. 277:42769-42774. http://dx.doi.org/10.1074/jbc.M206911200.
38. Huang HC, Nguyen T, Pickett CB. 2000. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NFE2- related factor 2. Proc. Natl. Acad. Sci. U. S. A. 97:12475-12480. http://dx.doi.org/10.1073/pnas.220418997.
39. Bloom DA, Jaiswal AK. 2003. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response elementmediated NAD(P)H:quinone oxidoreductase-1 gene expression. J. Biol. Chem. 278:44675-44682. http://dx.doi.org/10.1074/jbc.M307633200.
40. Niture SK, Jain AK, Jaiswal AK. 2009. Antioxidant-induced modification of INrf2 cysteine 151 and PKC-σ-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance. J. Cell Sci. 122:4452-4464. http://dx.doi.org/10.1242/jcs.058537.
41. Padmanabhan B, Tong KI, Kobayashi A, Yamamoto M, Yokoyama S. 2008. Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1. J. Synchrotron Radiat. 15:273-276. http://dx.doi.org/10.1107/S090904950705114X.
42. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, Yamamoto M. 2006. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 21:689-700. http://dx.doi.org/10.1016/j.molcel.2006.01.013.
43. Fujii S, Sawa T, Ihara H, Tong KI, Ida T, Okamoto T, Ahtesham AK, Ishima Y, Motohashi H, Yamamoto M, Akaike T. 2010. The critical role of nitric oxide signaling, via protein S-guanylation and nitrated cyclic GMP, in the antioxidant adaptive response. J. Bol. Chem. 285:23970- 23984. http://dx.doi.org/10.1074/jbc.M110.145441.
44. Karlsson R, Fält A. 1997. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J. Immunol. Methods 200:121-133. http://dx.doi.org/10.1016/S0022-1759(96)00195-0.
45. Lipschultz CA, Li Y, Smith-Gill S. 2000. Experimental design for analysis of complex kinetics using surface plasmon resonance. Methods 20:310- 318. http://dx.doi.org/10.1006/meth.1999.0924.
46. Chen Y, Inoyama D, Kong AN, Beamer LJ, Hu L. 2011. Kinetic analyses of Keap1-Nrf2 interaction and determination of the minimal Nrf2 peptide sequence required for Keap1 binding using surface plasmon resonance. Chem. Biol. Drug Des. 78:1014-1021. http://dx.doi.org/10.1111/j.1747-0285.2011.01240.x.
47. McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. 2006. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a "tethering" mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 281:24756-24768. http://dx.doi.org/10.1074/jbc.M601119200.
48. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI, Kim M, Nishito Y, Iemura S, Natsume T, Ueno T, Kominami E, Motohashi H, Tanaka K, Yamamoto M. 2010. The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell Biol. 12:213-223. http://dx.doi.org/10.1038/ncb2021.
49. Baird L, Llères D, Swift S, Dinkova-Kostova AT. 2013. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc. Natl. Acad. Sci. U. S. A. 110:15259-15264. http://dx.doi.org/10.1073/pnas.1305687110.